Featuring the open access citation advantage for research into poverty-related disease, Finland’s decision to join Plan S, and how ORCID can help the pharmaceutical industry.
Featuring the FDA’s proposal to begin enforcing fines for research funders who don’t report their clinical trial results, the potential harms of over zealous ‘industry bashing’, and the barbecue joint for high impact authors.
Featuring the story of open citations, the science of publishing, and the new open source peer-review platform.
Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
Featuring the ground-shaking new ‘Plan-S’ open access commitments, a critical look at the ‘moral high ground’ of academia, and open access: the movie.
Featuring the push to shine a light on peer review reports, worries about preprints in the press, and research on trial reporting levels in the top society journals.
Featuring the open access Twitter spat in full media orbit, Science’s new programme to build CC BY journals with partnered institutions, and the rights of the peer reviewer to access underlying data.
Featuring whether or not funder open access platforms are a good idea, the positive impact of Unpaywall, and explaining preprints to those new to Open Science.
Featuring the surprisingly sharp claws of predatory publishers, the problem with measuring research impact, and Elsevier’s acquisition of Aries Systems.
Featuring the release of the Foundations for Open Scholarship Strategy Development document, the addition of citation data to Altmetric, the launch of Participation Reports by Crossref, and The Francis Crick Institute’s commitment to open access and preprints.